Creo Medical has announced interim results for the 6-months to June 2025, reporting revenues up 40% YoY to £2.2m, and an improved operating loss of £10.0m, representing a c£5m improvement versus 1H24A. The company closed the period with cash of £20.5m, following the receipt of £24.9m of net cash from the sale of a 51% of Creo Medical Europe. The number of device users increased to 232 from 214 at the close of FY24, the company launched SpydrBlade and saw an increase in the number of sites using ....
